Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07109817 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Desloratadine to Prevent Taxane-induced Peripheral Neuropathy in Patients With Breast Cancer

Study acronym: DETOXp
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 2 months later Sep 2029 → Dec 2029
See other at-risk trials from Montefiore Medical Center

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date: Jun 2026 to Sep 2026
    • Primary completion pushed from Sep 2029 to Dec 2029
    • Study completion pushed from Sep 2030 to Dec 2030
    v9
  2. Recruitment openedv8 Show 4 more changesShow less
    • Primary completion pushed from Aug 2029 to Sep 2029
    • Study completion pushed from Aug 2030 to Sep 2030
    • Start date: May 2026 to Jun 2026
    • Site details revised
  3. Start date: Mar 2026 to May 2026
    • Primary completion pushed from Jun 2029 to Aug 2029
    • Study completion pushed from Jun 2030 to Aug 2030
    v7
  4. Primary completion date: Mar 2029 to Jun 2029
    • Study completion date: Mar 2030 to Jun 2030
    • Start date: Jan 2026 to Mar 2026
    v6
  5. Start date: Nov 2025 to Jan 2026
    • Primary completion date: Jan 2029 to Mar 2029
    • Study completion date: Jan 2030 to Mar 2030
    v5
Show 3 earlier versionsHide 3 earlier versions
  1. Start date: Oct 2025 to Nov 2025
    • Study description expanded, about 4 words
    v4
  2. Start date: Aug 2025 to Oct 2025
    • Primary completion date: Nov 2028 to Jan 2029
    • Study completion date: Nov 2029 to Jan 2030
    v3
  3. Primary endpoint revised
    • Eligibility criteria expanded, about 13 words
    • Secondary endpoints revised (8)
    • Study description expanded, about 5 words
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a double-blinded randomized controlled clinical trial that aims to study if desloratadine can reduce rates of peripheral neuropathy development in patients with breast cancer receiving taxane chemotherapy. Researchers will compare desloratadine to a placebo (look-alike substance with no drug) and use validated neurotoxicity and quality of life questionnaires to determine if desloratadine can be used to prevent or make taxane induced peripheral neuropathy (TPIN) symptoms better.
Trial Details
NCT Number NCT07109817
Lead Sponsor Montefiore Medical Center
Conditions
(from sponsor)		 Breast Cancer, Peripheral Neuropathy
Related terms Breast Neoplasms, Peripheral Nervous System Diseases
Enrollment 116 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov